Project: Development of a novel nasal therapy containing antimicrobial peptides to treat MRSA carriage
The aim of this project is to develop a nasal therapy with antimicrobial peptides (AMPs) to eradicate MRSA carriage. The synthetic AMPs that were previously developed by Madam Therapeutics (Madam) and Leiden University Medical Center (LUMC) have shown to be fully effective against antibiotic-resistant bacterial strains in in vitro models, including MRSA. At the end of this project, an AMP-based nasal therapy will be available, with associated Proof-of-Mechanism and safety data package.
| Acronym | NAS-AMP (Reference Number: 9795) |
| Duration | 01/01/2016 - 01/01/2019 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 3 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 21779 | Madam Therapeutics B.V. | Coordinator | Netherlands |
| 21780 | Leids Universitair Medisch Centrum | Partner | Netherlands |
| 21781 | SISAF Ltd | Partner | United Kingdom |
| 21782 | "Toxi-Coop" Toxicological Research Center Zrt | Partner | Hungary |